Orchard Therapeutics Plc (ORTX) Misses Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Orchard Therapeutics Extends Runway into 2024, Focusing HSC Gene Therapy Platform Exclusively on Severe Neurometabolic Diseases and Research Platform
March 30, 2022 7:00 AM EDTLibmeldy European launch momentum building with multiple MLD patients treated and strong recognition of value proposition; U.S. BLA filing of OTL-200 on track for late 2022 / early 2023
Broad research platform presents opportunities for larger indications and partnerships; preclinical POC data in NOD2 Crohns disease expected by year end and IND filing planned in 2024
Plan to seek strategic alternatives for primary immunodeficiency programs, including OTL-103 in WAS
Refined portfolio and 30% proposed workforce reduction extend cash runway into 2024
BOSTON and LONDON, March... More
